VCI Wealth Management LLC Has $2.81 Million Holdings in Johnson & Johnson (NYSE:JNJ)

VCI Wealth Management LLC boosted its stake in Johnson & Johnson (NYSE:JNJ) by 32.9% during the 4th quarter, HoldingsChannel reports. The fund owned 19,399 shares of the company’s stock after acquiring an additional 4,805 shares during the quarter. Johnson & Johnson comprises 1.2% of VCI Wealth Management LLC’s investment portfolio, making the stock its 21st largest position. VCI Wealth Management LLC’s holdings in Johnson & Johnson were worth $2,805,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in JNJ. State Street Corp boosted its holdings in Johnson & Johnson by 0.9% during the third quarter. State Street Corp now owns 134,245,811 shares of the company’s stock worth $21,755,874,000 after purchasing an additional 1,154,088 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Johnson & Johnson by 1.8% during the 3rd quarter. Geode Capital Management LLC now owns 56,106,884 shares of the company’s stock worth $9,064,149,000 after buying an additional 1,004,763 shares during the last quarter. FMR LLC grew its holdings in shares of Johnson & Johnson by 7.4% in the 3rd quarter. FMR LLC now owns 18,316,920 shares of the company’s stock valued at $2,968,440,000 after acquiring an additional 1,265,748 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Johnson & Johnson by 0.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 17,639,368 shares of the company’s stock worth $2,858,543,000 after acquiring an additional 102,502 shares in the last quarter. Finally, Franklin Resources Inc. boosted its position in Johnson & Johnson by 11.4% during the third quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company’s stock valued at $2,721,355,000 after purchasing an additional 1,729,281 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of the business’s stock in a transaction on Thursday, December 12th. The stock was purchased at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $147,220. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Trading Down 0.5 %

Shares of JNJ stock opened at $152.09 on Friday. The stock has a 50 day simple moving average of $147.67 and a 200 day simple moving average of $156.07. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The stock has a market cap of $366.17 billion, a P/E ratio of 22.87, a price-to-earnings-growth ratio of 2.43 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. Johnson & Johnson’s quarterly revenue was up 5.3% on a year-over-year basis. During the same period in the prior year, the firm posted $2.29 EPS. On average, research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.26%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

Analyst Upgrades and Downgrades

JNJ has been the topic of a number of analyst reports. Leerink Partners dropped their price objective on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Argus upgraded shares of Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Wolfe Research began coverage on Johnson & Johnson in a report on Friday, November 15th. They set an “outperform” rating and a $190.00 price target for the company. Finally, Barclays upped their price objective on Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research note on Tuesday. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $170.44.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.